Skip to main content
Top
Published in: BMC Ophthalmology 1/2017

Open Access 01-12-2017 | Research article

Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab

Authors: Lucia Gonzalez-Buendia, Santiago Delgado-Tirado, M. Rosa Sanabria, Itziar Fernandez, Rosa M. Coco

Published in: BMC Ophthalmology | Issue 1/2017

Login to get access

Abstract

Background

To analyze predictors and develop predictive models of anatomic outcome in neovascular age-related macular degeneration (AMD) treated with as-needed ranibizumab after 4 years of follow-up.

Methods

A multicenter consecutive case series non-interventional study was performed. Clinical, funduscopic and OCT characteristics of 194 treatment-naïve patients with AMD treated with as-needed ranibizumab for at least 2 years and up to 4 years were analyzed at baseline, 3 months and each year until the end of the follow-up. Baseline demographic and angiographic characteristics were also evaluated. R Statistical Software was used for statistical analysis. Main outcome measure was final anatomic status.

Results

Factors associated with less probability of preserved macula were diagnosis in 2009, older age, worse vision, presence of atrophy/fibrosis, pigment epithelium detachment, and geographic atrophy/fibrotic scar/neovascular AMD in the fellow eye. Factors associated with higher probability of GA were presence of atrophy and greater number of injections, whereas male sex, worse vision, lesser change in central macular thickness and presence of fibrosis were associated with less probability of GA as final macular status. Predictive model of preserved macula vs. GA/fibrotic scar showed sensibility of 77.78% and specificity of 69.09%. Predictive model of GA vs. fibrotic scar showed sensibility of 68.89% and specificity of 72.22%.

Conclusions

We identified predictors of final macular status, and developed two predictive models. Predictive models that we propose are based on easily harvested variables, and, if validated, could be a useful tool for individual patient management and clinical research studies.
Literature
1.
go back to reference Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.CrossRefPubMed Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, Wong TY. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2(2):e106–16.CrossRefPubMed
2.
go back to reference Hanout M, Ferraz D, Ansari M, Maqsood N, Kherani S, Sepah YJ, Rajagopalan N, Ibrahim M, Do DV, Nguyen QD. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int. 2013;2013:830837.CrossRefPubMedPubMedCentral Hanout M, Ferraz D, Ansari M, Maqsood N, Kherani S, Sepah YJ, Rajagopalan N, Ibrahim M, Do DV, Nguyen QD. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. Biomed Res Int. 2013;2013:830837.CrossRefPubMedPubMedCentral
3.
go back to reference Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122(1):153–61.CrossRefPubMed Tanaka E, Chaikitmongkol V, Bressler SB, Bressler NM. Vision-threatening lesions developing with longer-term follow-up after treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122(1):153–61.CrossRefPubMed
4.
go back to reference Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120(2):334–41.CrossRefPubMed Kumar N, Mrejen S, Fung AT, Marsiglia M, Loh BK, Spaide RF. Retinal pigment epithelial cell loss assessed by fundus autofluorescence imaging in neovascular age-related macular degeneration. Ophthalmology. 2013;120(2):334–41.CrossRefPubMed
5.
go back to reference Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–66.CrossRefPubMed Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, Huang J, Ying GS, Hagstrom SA, Winter K, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–66.CrossRefPubMed
6.
go back to reference Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–61.CrossRefPubMed Grunwald JE, Daniel E, Huang J, Ying GS, Maguire MG, Toth CA, Jaffe GJ, Fine SL, Blodi B, Klein ML, et al. Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(1):150–61.CrossRefPubMed
7.
go back to reference Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.CrossRefPubMed Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, Fahrbach K, Probst C, Sledge I. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115(1):116–26.CrossRefPubMed
8.
go back to reference Coco RM, Sanabria MR, Castrejon M, Lopez-Galvez MI, Monje-Fernandez L, Fernandez-Munoz M, Anton A, de Juan-Marcos L, Villaron-Alvarez S, Fernandez I. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmol. 2014;14:138.CrossRefPubMedPubMedCentral Coco RM, Sanabria MR, Castrejon M, Lopez-Galvez MI, Monje-Fernandez L, Fernandez-Munoz M, Anton A, de Juan-Marcos L, Villaron-Alvarez S, Fernandez I. Funduscopic results after 4-year follow-up treatment with ranibizumab for age-related macular degeneration in a region of Spain. BMC Ophthalmol. 2014;14:138.CrossRefPubMedPubMedCentral
9.
go back to reference Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046–50.CrossRefPubMed Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snellen visual acuity measurements. Retina. 2010;30(7):1046–50.CrossRefPubMed
10.
go back to reference Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol. 1995;39(5):367–74.CrossRefPubMed Bird AC, Bressler NM, Bressler SB, Chisholm IH, Coscas G, Davis MD, de Jong PT, Klaver CC, Klein BE, Klein R, et al. An international classification and grading system for age-related maculopathy and age-related macular degeneration. The international ARM epidemiological study group. Surv Ophthalmol. 1995;39(5):367–74.CrossRefPubMed
12.
go back to reference Genolini C, Lacombe A, Ecochard R, Subtil F. CopyMean: a new method to predict monotone missing values in longitudinal studies. Comput Methods Prog Biomed. 2016;132:29–44.CrossRef Genolini C, Lacombe A, Ecochard R, Subtil F. CopyMean: a new method to predict monotone missing values in longitudinal studies. Comput Methods Prog Biomed. 2016;132:29–44.CrossRef
13.
go back to reference Akaike H. Information theory and an extension of the maximum likelihood principle. In: 2nd International symposium on information theory; 1973. p. 267–81. Akaike H. Information theory and an extension of the maximum likelihood principle. In: 2nd International symposium on information theory; 1973. p. 267–81.
16.
go back to reference Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev. 1950;78:1–3.CrossRef Brier GW. Verification of forecasts expressed in terms of probability. Mon Weather Rev. 1950;78:1–3.CrossRef
17.
go back to reference Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley; 1989. p. 147–56. Hosmer D, Lemeshow S. Applied logistic regression. New York: Wiley; 1989. p. 147–56.
18.
go back to reference Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRefPubMedPubMedCentral Robin X, Turck N, Hainard A, Tiberti N, Lisacek F, Sanchez JC, Muller M. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.CrossRefPubMedPubMedCentral
19.
go back to reference de Sisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Invest Ophthalmol Vis Sci. 2014;55(11):7093–103.CrossRefPubMed de Sisternes L, Simon N, Tibshirani R, Leng T, Rubin DL. Quantitative SD-OCT imaging biomarkers as indicators of age-related macular degeneration progression. Invest Ophthalmol Vis Sci. 2014;55(11):7093–103.CrossRefPubMed
20.
go back to reference Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50(5):2044–53.CrossRefPubMed Seddon JM, Reynolds R, Maller J, Fagerness JA, Daly MJ, Rosner B. Prediction model for prevalence and incidence of advanced age-related macular degeneration based on genetic, demographic, and environmental variables. Invest Ophthalmol Vis Sci. 2009;50(5):2044–53.CrossRefPubMed
21.
go back to reference Buitendijk GH, Rochtchina E, Myers C, van Duijn CM, Lee KE, Klein BE, Meuer SM, de Jong PT, Holliday EG, Tan AG, et al. Prediction of age-related macular degeneration in the general population: the three continent AMD consortium. Ophthalmology. 2013;120(12):2644–55.CrossRefPubMedPubMedCentral Buitendijk GH, Rochtchina E, Myers C, van Duijn CM, Lee KE, Klein BE, Meuer SM, de Jong PT, Holliday EG, Tan AG, et al. Prediction of age-related macular degeneration in the general population: the three continent AMD consortium. Ophthalmology. 2013;120(12):2644–55.CrossRefPubMedPubMedCentral
22.
go back to reference Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, Comparison of Age-related Macular Degeneration Treatments Trials Research G. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16.CrossRefPubMed Grunwald JE, Pistilli M, Ying GS, Maguire MG, Daniel E, Martin DF, Comparison of Age-related Macular Degeneration Treatments Trials Research G. Growth of geographic atrophy in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2015;122(4):809–16.CrossRefPubMed
23.
go back to reference Schutze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(6):1100–14. e1101CrossRefPubMedPubMedCentral Schutze C, Wedl M, Baumann B, Pircher M, Hitzenberger CK, Schmidt-Erfurth U. Progression of retinal pigment epithelial atrophy in antiangiogenic therapy of neovascular age-related macular degeneration. Am J Ophthalmol. 2015;159(6):1100–14. e1101CrossRefPubMedPubMedCentral
24.
go back to reference Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–9.CrossRefPubMed Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, Group S-US. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292–9.CrossRefPubMed
25.
go back to reference Kuehlewein L, Dustin L, Sagong M, Hariri A, Mendes TS, Rofagha S, Bhisitkul RB, Sadda SR. Predictors of macular atrophy detected by Fundus autofluorescence in patients with Neovascular age-related macular degeneration after long-term Ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):224–31.CrossRefPubMed Kuehlewein L, Dustin L, Sagong M, Hariri A, Mendes TS, Rofagha S, Bhisitkul RB, Sadda SR. Predictors of macular atrophy detected by Fundus autofluorescence in patients with Neovascular age-related macular degeneration after long-term Ranibizumab treatment. Ophthalmic Surg Lasers Imaging Retina. 2016;47(3):224–31.CrossRefPubMed
26.
go back to reference Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–83.CrossRefPubMed Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW Jr, Esquiabro M. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol. 2007;143(4):566–83.CrossRefPubMed
27.
go back to reference Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58. e41CrossRefPubMed Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW Jr, Esquiabro M. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol. 2009;148(1):43–58. e41CrossRefPubMed
28.
go back to reference Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF. Association of Baseline Characteristics and Early Vision Response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology. 2015;122(12):2523–31. e2521CrossRefPubMedPubMedCentral Ying GS, Maguire MG, Daniel E, Ferris FL, Jaffe GJ, Grunwald JE, Toth CA, Huang J, Martin DF. Association of Baseline Characteristics and Early Vision Response with 2-year vision outcomes in the comparison of AMD treatments trials (CATT). Ophthalmology. 2015;122(12):2523–31. e2521CrossRefPubMedPubMedCentral
Metadata
Title
Predictive models of long-term anatomic outcome in age-related macular degeneration treated with as-needed Ranibizumab
Authors
Lucia Gonzalez-Buendia
Santiago Delgado-Tirado
M. Rosa Sanabria
Itziar Fernandez
Rosa M. Coco
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Ophthalmology / Issue 1/2017
Electronic ISSN: 1471-2415
DOI
https://doi.org/10.1186/s12886-017-0544-x

Other articles of this Issue 1/2017

BMC Ophthalmology 1/2017 Go to the issue